Left ventricular failure
Methodology & AI Transparency ⓘ
Left ventricular failure Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Left ventricular failure (I50.1; Heart & Cardiovascular Disease) utilize cardiopulmonary biomarker stratification [Left ventricular failure I50.1] and objective Apolipoprotein B (ApoB) [Left ventricular failure I50.1] targets (< 70 mg/dL (I50.1)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Mapped to Heart & Cardiovascular Disease under ICD-10-CM I50.1 for Left ventricular failure clinical workups.
- 3 Typical cash cost range: Clinicians assessing Left ventricular failure focus on electrical conduction pathway in Left ventricular failure (I50.1: remodeling) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Left ventricular failure: Apolipoprotein B (ApoB) [Left ventricular failure I50.1] (< 70 mg/dL (I50.1)) and Left Ventricular Ejection in Left ventricular failure (I50.1: Fraction (LVEF)).
Ask our AI Specialists anything about Left ventricular failure
What Is Left ventricular failure?
Physicians managing Left ventricular failure (I50.1; Heart & Cardiovascular Disease) utilize cardiopulmonary biomarker stratification [Left ventricular failure I50.1] and objective Apolipoprotein B (ApoB) [Left ventricular failure I50.1] targets (< 70 mg/dL (I50.1)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Left ventricular failure (ICD-10 I50.1) is driven by electrical conduction pathway in Left ventricular failure (I50.1: remodeling); specialists in Heart & Cardiovascular Disease monitor Left Ventricular Ejection in Left ventricular failure (I50.1: Fraction (LVEF)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Left ventricular failure (I50.1): reduced exercise tolerance in Left ventricular failure (I50.1: and premature cardiovascular)
- • Secondary Left ventricular failure clinical sign: exertional chest pressure in Left ventricular failure (I50.1: or retrosternal tightness)
- • Symptom flares in Left ventricular failure correlating with Apolipoprotein B (ApoB) [Left ventricular failure I50.1] deviation outside < 70 mg/dL (I50.1)
- • Functional heart & vascular impact requiring cardiopulmonary biomarker stratification [Left ventricular failure I50.1] evaluation (I50.1)
Left ventricular failure Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I50.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Left ventricular failure I50.1] | < 70 mg/dL (I50.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Left ventricular failure (I50.1: Fraction (LVEF)) | 55% – 70% (I50.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: NT-proBNP [Left ventricular failure I50.1] | < 100 pg/mL (I50.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Left ventricular failure
Treatment selection for Left ventricular failure depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Left ventricular failure)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Obstructive sleep apnoea syndrome and left ventricular: What a 5,550-Participant Study Found The present meta-analysis expands previous information on the relationship between OSA and echocardiographic LVH, so far based on individual studies. Journal of hypertension • 2020-09-15 • Meta-Analysis | N = 5,550 | 94/100 | PMID 32371766 ↗ |
| New Insights on Electrocardiographic Left Ventricular Hypertrophy Predicts heart and blood vessel: What a 33,357-Participant Study Found Baseline Cornell voltage LVH is associated with increased CV morbidity and all-cause mortality in treated hypertensive patients independent of treatment modality and other CV risk factors. American journal of hypertension • 2017-09-01 • Randomized Controlled Trial | N = 33,357 | 90/100 | PMID 28430947 ↗ |
| Can This Approach Help? Inside the Latest Research on Echocardiographic Left Ventricular Reverse Remodeling After 18 Months of Treatment of patients with stage I high blood pressure for 18 months promotes favorable effects in the LA and LV remodeling. American journal of hypertension • 2018-02-09 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 29036504 ↗ |
| Can This Approach Help? Inside the Latest Research on Subclinical cardiac damage monitoring in breast cancer patients treated with an Our results emphasize the crucial role of cardioprotective measures in mitigating adverse effects, highlighting RT as having negligible influence on cardiac performance. La Radiologia medica • 2024-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39436588 ↗ |
| Benefits and safety of intravenous OPC-61815 vs. Oral tolvaptan: Which Works Better for Congestive heart failure? OPC-61815 (16-mg injection) was confirmed as non-inferior to oral tolvaptan (15-mg tablet) in patients with congestive heart failure and inadequate response to diuretics; no new safety. ESC heart failure • 2022-10-15 • Phase III Randomized Trial | N = 149 | 88/100 | PMID 35794067 ↗ |
Left ventricular failure Patient Community & “People Like Me” Threads
Filter Left ventricular failure community threads and patient logs by age, biological sex, dosage, and treatment duration.